InMode Ltd (INMD)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $763.61M
Last updated: Nov 17, 2026 at 11:06 AM ET
InMode Ltd (INMD) P/E Ratio & Valuation History
InMode (INMD) trades at 9.6x trailing earnings and 2.1x sales. Its P/E of 9.6x is below its 5-year median of 9.8x. Its forward P/E is 9.3x. The median P/E across 7 similar companies is 27.8x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 3.2% higher over the next year. Its free cash flow yield is 9.4%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 9.6x |
| Forward P/E | 9.3x |
| Price to sales | 2.1x |
| Price to book | 1.2x |
| EV/EBITDA | 4.9x |
| Price to FCF | 10.7x |
| EV/FCF | 5.2x |
| PEG | 2.9 |
| FCF yield | 9.4% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 9.6x | 9.8x | N/A |
| P/S | 2.1x | 3.8x | N/A |
| P/B | 1.2x | 2.1x | N/A |
Valuation History
Over the 7 year ends shown, its P/E ranged from 8.7x in 2023 to 34.4x in 2021.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $14.69 | 9.3x | 2.6x | 1.4x |
| 2024 | $16.70 | 9.4x | 3.4x | 1.7x |
| 2023 | $22.24 | 8.7x | 3.9x | 2.4x |
| 2022 | $35.70 | 14.7x | 6.7x | 5.6x |
| 2021 | $70.58 | 34.4x | 17.0x | 14.7x |
| 2020 | $23.74 | 22.4x | 9.7x | 7.9x |
| 2019 | $19.60 | 27.6x | 9.1x | 9.3x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About INMD
What is INMD's forward P/E ratio?
InMode has a forward P/E ratio of 9.3x.
Is INMD stock overvalued?
GNG's valuation label for INMD is Undervalued. Its P/E of 9.6x compares with a median of 27.8x across 7 similar companies.
What is INMD's price to sales ratio?
InMode has a price to sales ratio of 2.1x.
What is InMode's average P/E ratio over 5 years?
InMode's median P/E over the last 5 years is 9.8x, from 60 month-end values through Oct 2026.
What is INMD's PEG ratio?
InMode has a PEG ratio of 2.9.
INMD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors